Journal article

Dissecting the Heterogeneity of Triple-Negative Breast Cancer

Otto Metzger-Filho, Andrew Tutt, Evandro de Azambuja, Kamal S Saini, Giuseppe Viale, Sherene Loi, Ian Bradbury, Judith M Bliss, Hatem A Azim, Paul Ellis, Angelo Di Leo, Jose Baselga, Christos Sotiriou, Martine Piccart-Gebhart

Journal of Clinical Oncology | AMER SOC CLINICAL ONCOLOGY | Published : 2012

Grants

Awarded by Cancer Research UK


Funding Acknowledgements

Employment or Leadership Position: None Consultant or Advisory Role: Andrew Tutt, sanofi-aventis (U), AstraZeneca (U), Eisai (C), Clovis (C); Judith M. Bliss, sanofi-aventis (U); Hatem A. Azim Jr, Celgene (C); Paul Ellis, Roche (C), GlaxoSmithKline (C), sanofi-aventis (C), Esai (C); Angelo Di Leo, AstraZeneca (C), Pfizer (C), sanofi-aventis (C); Jose Baselga, sanofi-aventis (C); Martine Piccart-Gebhart, sanofi-aventis (C), Amgen (C), Roche (C), GlaxoSmithKline (C), PharmaMar (C) Stock Ownership: None Honoraria: Andrew Tutt, AstraZeneca, sanofi-aventis; Paul Ellis, Roche, Esai, sanofi-aventis; Angelo Di Leo, AstraZeneca, Pfizer, sanofi-aventis; Martine Piccart-Gebhart, sanofi-aventis, Amgen, Roche, GlaxoSmithKline, PharmaMar Research Funding: Andrew Tutt, sanofi-aventis; Judith M. Bliss, sanofi-aventis; Angelo Di Leo, AstraZeneca Expert Testimony: None Other Remuneration: Andrew Tutt, AstraZeneca, sanofi-aventis; Judith M. Bliss, sanofi-aventis